Background. Bulimia nervosa is a severe eating disorder that can be managed using a 8
inconsistency between the direct and indirect evidence. 23
Conclusions. The analysis suggested that the treatments that are most likely to achieve full 24 remission are individual CBT (specific to eating disorders) and guided cognitive behavioural 25 self-help, although no firm conclusions could be drawn due to the limited evidence base. 26
There is a need for further research on the maintenance of treatment effects and the 27 mediators of treatment outcome. 28 2017). Network meta-analysis (NMA) has advantages over standard pairwise meta-analysis 56 in that (1) all the treatments that have been tested in RCTs can be simultaneously compared 57 to each other in one analysis; and (2) their effects can be estimated relative to each other 58 and to a common reference condition (such as a wait list). Estimates of the relative effects of 59 pairs of treatments that have often, rarely, or never been directly compared in an RCT can 60 be calculated. Consequently, an NMA overcomes some of the limitations of a traditional 61 meta-analysis in which conclusions are largely restricted to comparisons between treatments 62 that have been directly compared in RCTs (Dias et al. 2013) . 63
An NMA was developed and conducted of all psychological, pharmacological, and 64 combination therapies that are used for the treatment of adult BN, and which have been 65 tested in RCTs. This NMA was used to inform the new national clinical guidance for eating 66 disorders in England released by the National Institute for Health and Care Excellence 67 (NICE, 2017). The guideline was developed by a Guideline Committee, an independent 68 multi-disciplinary team consisting of clinical academics, health professionals and service 69 users and carer representatives with expertise and experience in the field of eating 70 disorders. This article reports the findings of the NMA that was conducted to inform the NICE 71 guideline on the most effective treatments for BN in adults. 72
METHODS

74
Search strategy
75
A search for published and unpublished studies on the treatment of adults with eating 76 disorders was conducted in the databases Embase, Medline, PsycINFO and Central to 77 inform the NICE guideline. All databases were searched from their inception to July 2016 78 and no language limits were set. The strategy used terms covering all eating disorders, in 79 accordance with the NICE guideline scope. The balance between sensitivity (the power to 80 identify all studies on a particular topic) and specificity (the ability to exclude irrelevant 81 studies from the results) was carefully considered, and a decision was made to utilise a 82 broad, population-based approach to the search in order to maximise retrieval in a wide 83 range of areas. To aid retrieval of relevant and sound studies, 'filters' were used (where 84 appropriate) to limit the search results to RCTs. See Supplementary Appendix 1 for full 85 details of the search terms used. 86
Selection criteria
87
A systematic review of interventions for BN was carried out according to Preferred Reporting 88
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2009 ). 89
The titles and abstracts of identified studies were screened by two reviewers against 90 inclusion criteria specified in the guideline review protocols, until a good inter-rater reliability 91 was observed (percentage agreement ≥90%, or Kappa statistic K>0.60) (NICE, 2017). Any 92 disagreements between raters were resolved through discussion. Once full versions of the 93 selected studies were acquired for assessment, full studies were checked independently by 94 two reviewers, with any differences being resolved with discussion. Data were extracted on 95 the study characteristics, aspects of the methodological quality, outcome data, and risk of 96
bias. 97
RCTs for the systematic review of treatments for BN were included if they reported on 98 treatments for people aged at least 18 years who fulfilled diagnostic criteria for BN (i.e. DSM-99 IV). Two reviewers independently assessed eligibility: studies were included if they were 100
RCTs examining psychological, pharmacological, or combination therapies compared with a 101 wait list, pill placebo, or another active treatment. Nutritional management was not 102 considered in the review as this was seen as an add on to treatments for people with BN. 103 Also, only treatments available and licensed in the UK for BN were included. 104
According to the NICE Guideline Committee's expert view, it was important to differentiate 105 between CBT-specific to eating disorders (CBT-ED) and generic CBT. CBT-ED is the 106 leading form of treatment for BN that places emphasis on the eating disorder 107 psychopathology and may have some differences in efficacy when compared with CBT non-108 specific to eating disorders. It was also considered important to distinguish between group 109 and individual treatments, and between pure and guided cognitive behavioural self-help 110 because there may be some differences in efficacy and also on cost effectiveness, which is 111 an important factor when making recommendations for NICE guidelines. 112
Network meta-analysis
113
To take all trial information into consideration, network meta-analytic techniques (mixed 114 treatment comparisons) were employed to synthesise evidence. The critical outcomes in the 115 systematic review conducted for the NICE guideline were remission, long-term recovery, and 116 binge eating. The guideline systematic review of the clinical literature identified only one 117 dichotomous outcome that could be utilised in the NMA -full remission at the end of 118 treatment -as the reporting of the other outcome measures was inconsistent across the 119 trials. The NMA was also used to inform a cost-effectiveness analysis and the Guideline 120
Committee was of the view that full remission at the end of treatment was an important 121 outcome to pursue in the economic evaluation. 122
The identified RCTs employed a range of definitions of full remission, utilising criteria such 123 as abstinence from binge eating and purging. Following consultation with the NICE Guideline 124
Committee, RCTs were included only if they defined full remission as either the abstinence 125 of bulimia-related symptoms over a minimum of a two week period, or as no longer meeting 126
DSM-IV criteria for BN (including cognitive elements). The definition of remission was 127
decided before selection of studies. A number of excluded studies employed shorter time 128 frames or lesser symptom reduction. However, stricter criteria for defining full remission were 129 used because the fluctuating nature of symptom severity and gaps between behaviours in 130 BN mean that a shorter time period would not be clinically meaningful. In studies where the 131 time frame for remission was unclear, the Guideline Committee was consulted to decide 132 whether the study should be included in the review. 133
A network of treatments included in the systematic review, for which data on full remission at 134 end of treatment were available, was designed. Only treatments that were connected to the 135 network were considered. Treatment-as-usual arms were excluded, since the definitions of 136 'treatment-as-usual' varied across the studies and were therefore not informative to the 137 Guideline Committee. Head-to-head comparisons of no interest (such as interventions not 138 available or licensed for BN in the UK, as well as controls of no interest) were excluded from 139 the analysis unless they allowed indirect comparisons between interventions of interest (see 140
Supplementary Appendix 2 for details of the included studies in the NMA). An intention to 141 treat (ITT) analysis was adopted when estimating full remission (that is, all randomised 142 patients were included and anyone discontinuing treatment, for whatever reason, was 143 assumed not to be in remission). The flowchart diagram for the NMA is provided in Figure 1 . 144
Insert Figure 1 145
The Committee made an a priori assumption that there would need to be at least 200 people 146 randomised to a treatment across all included trials in the NMA for them to make a 147 recommendation with confidence. 148 
Statistical analysis
Continuity correction 163
In the dataset, several studies reported zero events of interest in some arms (that is, the 164 number of people achieving full remission was zero). Combining such data can be 165 problematic: when zero events occur in some arms of a study, the log-odds ratio becomes 166 undefined (as does the variance), which causes problems in the analysis and precludes the 167 estimation of relative effects. As a result, continuity corrections are needed. Using a 168 continuity correction for studies with zero counts allows the log-odds ratio to be estimated, 169 and hence allows synthesis via standard NMA methods. There are many possible continuity 170 correction methods (Sweeting et al. 2004 ). In the present study, a continuity correction of 0.5 171 was added to both the number of events and the number of non-events across all study 172 arms, in studies in which one or more (but not all) arms had zero events. 173
Inconsistency checks
174
A basic assumption of an NMA is that direct and indirect evidence estimate the same 175 parameter. That is, the relative effect between A and B measured directly from an A versus 176 B trial is the same as the relative effect between A and B estimated indirectly from A versus 177 C and B versus C trials. Inconsistency arises when there is a conflict between direct 178 evidence (from an A versus B trial) and indirect evidence (gained from A versus C and B 179 versus C trials). This consistency assumption has also been termed the similarity or 180 transitivity assumption (Mavridis et al. 2015) .
RESULTS
189
Identified studies and treatments 
Treatment outcomes 229
The posterior median odds ratios (OR) and 95% CrI for each treatment for achieving full 230 remission at the end of treatment compared to every other treatment are reported in Table 1 . 231
Compared with wait list, individual CBT-ED (OR 3.89, 95% CrI 1.19 to 14.02), guided 232 cognitive behavioural self-help (OR 3.81, 95% CrI 1.51 to 10.90), pure cognitive behavioural 233 self-help (OR 3.49, 95% CrI 1.20 to 11.21), group CBT-ED (OR 7.67, 95% CrI 1.51 to 234 55.66), and group BT (OR 28.70, 95% CrI 3.11 to 455.3) were significantly better at 235 achieving full remission at the end of treatment. Group BT was also better than IPT, 236 fluoxetine, individual BT, and relaxation. However, as indicated by the very wide 95% CrI, 237 there was high uncertainty regarding the treatment effects of group BT and group CBT-ED. 238
These therapies had very small numbers randomised across all studies and, as a result, 239 their effects were very uncertain. Although there were differences in the mean effects 240 between any other treatments, these were not statistically significant. The posterior median 241 log odds ratios (LOR) and 95% CrI for each treatment compared to every other for achieving 242 full remission at the end of treatment as estimated by the NMA (and, where available, the 243 respective results from the pairwise analysis) are provided in Supplementary Appendix 9. 244
The NMA and pairwise results were in agreement in all cases, which strengthens the results 245 of the NMA. 246 Figure 3 shows the ORs (on a log-scale) in remission compared to wait list. Most of the 247 treatments had very wide CrI and crossed the line of no effect. Most CrI also overlapped, 248 indicating no difference between the treatments. 249
Insert Table 1 250
Insert Figure 3 . Table 2 shows the 255 posterior median ranks and the associated 95% CrI. 256
Insert Table 2 257
The full results of the NMA are provided in Supplementary Appendix 11. 258
DISCUSSION
260
To our knowledge, this is the first reported NMA in people with BN. Only one previous NMA 261 in people with eating disorders was identified, examining the effectiveness of psychological 262 and pharmacological interventions for binge-eating disorder (Peat et al. 2017 ). Overall, the 263 results of the present NMA suggest that group BT, group CBT-ED, individual CBT-ED and 264 guided cognitive behavioural self-help are more effective than other treatments in achieving 265 full remission at the end of treatment. The findings for group BT and group CBT-ED were 266 based on very small numbers randomised (N < 70), and were characterised by very wide 267
CrI. Similarly, the evidence for other treatments, with the exception of IPT, was limited. 268
However, the mean effects for these treatments suggest a less good outcome when 269 compared with cognitive or behavioural therapies. As a result, individual CBT-ED and guided 270 cognitive behavioural self-help are the treatments for which there is the most reliable 271 evidence. Also, the inconsistency checks did not identify any significant inconsistency 272 between the direct and indirect evidence included in the NMA, which strengthens the 273 conclusions of the analysis. 274
Not all trials identified in the systematic review provided data on full remission. 'Full 275 remission' was not clearly defined in some RCTs, and there was wide variation in its 276 definition when it was reported. In particular, a number of RCTs were excluded because 277 remission was defined as abstinence from bulimia-related symptoms over a period of less 278 than 2 weeks. According to the NICE Guideline Committee's expert opinion only abstinence 279 from bingeing over and above two weeks should be considered. Although this two-week 280 period was seen as a relatively weak definition, more stringent inclusion criteria would have 281 excluded the majority of studies since only few of them had longer reported periods. 282
It is acknowledged that not meeting full DSM-IV criteria is not the same as abstinence from 283 binge eating and compensatory behaviours, and it could potentially include people in partial 284 remission. However, given a limited evidence base the committee made a decision to 285 include such studies. Use of the DSM-V criteria would have been more inclusive but DSM-IV 286 criteria was still in operation when nearly all of the studies were conducted. 287
It should also be noted that papers used inconsistent definitions of behaviour change. Future 288 research needs to adopt consistent and rigorous definitions. It is proposed that 'abstinence' 289 be defined as (1) no objective binges or purging behaviours over the previous three months 290 and (2) being not underweight. Similarly, 'full remission' should be defined as abstinence, 291 plus attitudes towards eating, weight and shape within one standard deviation of the 292 community range for the relevant population. 293
The ITT analysis meant that all participants were analysed in the group to which they had 294 been randomized and all study non-completers were assumed to not be in remission. This 295 strategy was supported by the NICE guideline committee and provides a conservative 296 estimate of treatment effects. 297
It was not possible to investigate whether the end of treatment effects persisted or 298 diminished in the long term because most trials stopped at the end of treatment (usually at 299 16 weeks). Hence, there was insufficient evidence to inform an NMA using remission data at 300 long-term follow-up. Also, even though we included only those treatments available and 301 licensed for use in the UK, only one trial was excluded on the grounds of being of no interest 302 (Pope et al. 1989 , which compared trazodone with pill placebo). The findings should 303 therefore be of interest to an international audience. 304
One limitation of the study is that the literature search is over a year old. However, a 305 literature search on PubMed (conducted March 2018) failed to identify any relevant new 306
RCTs. 307
The finding that, among the treatments with a robust evidence base, individual CBT-ED 308 appears to be the most effective option to achieve remission at the end of treatment for 
treatments. 325
The present analysis found no convincing evidence for the effectiveness of pharmacological 326 treatments although few studies provided direct comparisons between psychological 327 therapies and pharmacological treatments. 328
Taking all these factors into account, the NICE guideline recommended that bulimia-329 nervosa-focused guided self-help should be offered as the first treatment for adults with BN 330 in a stepped care treatment strategy, with the second step being individual eating-disorder-331 focused cognitive behavioural therapy (CBT-ED) (NICE, 2017) . 332
Overall the evidence base was limited, in particular for a range of treatments. There is a 333 clear need for well-conducted head-to-head studies that examine the effectiveness of 334 pharmacological, individual as well as group psychological, and combined pharmacological 335 and psychological therapies compared to each other for adults with BN. In particular, long-336 term comparative outcome data are needed. 337
CONTRIBUTORS
338
EK contributed to the NMA analyses, conducted inconsistency checks 339 ES carried out the NMA and the associated analyses, and wrote the first draft of the 340 manuscript 341 IM contributed to the study conception, planning, and NMA analyses 342 LF contributed to carrying out the systematic reviews, data extraction, proof reading and 343
copy editing 344
LSa contributed to carrying out the systematic reviews, and data extraction 345 The funder of the study had no further role in study design, data collection, data analysis, 368 data interpretation, or writing of the report. All authors had full access to all the data in the 369 study and had final responsibility for the decision to submit for publication. 370
CONFLICTS OF INTERESTS
371
ES, IM, LF, LSa, ST, and TK received support from the NGA, which was in receipt of funding 372 from NICE for the submitted work. 373 SD and EK received support from the NICE Guidelines Technical Support Unit, University of 374 Bristol, with funding from the Centre for Guidelines (NICE). The funder had no role in study 375 design, data collection, and analysis, decision to publish, or preparation of the manuscript. 376 CGF is the author of research papers, review articles and books that have commented on 377 the effectiveness of various treatments for eating disorders (including BN). Royalties 378 received from publishers of the books concerned. CGF held (paid and unpaid) training 379 workshops for clinicians on eating disorders; on eating disorder treatment in general; and on 380 specific treatments for eating disorders (CBT; IPT; guided self-help). CGF is involved in 381 developing an online means of training therapists in a specific treatment for eating disorders, 382 including CBT. CGF is supported by a Principal Fellowship from the Wellcome Trust 383
(046386). 384
LSr has no declarations of conflict of interest. 385
HT is teaching and conducting research/publications in CBT. She is also involved in the 386 development and evaluation of brief CBT interventions for eating disorders and in an 387 effectiveness study of CBT when delivered in routine clinical settings. 388 GW published books and a range of papers and book chapters on CBT for eating disorders; 389 regularly gives workshops on evidence-based CBT for eating disorders. 390
SUPPORTING INFORMATION
391
Additional Supporting Information may be found in the online version of this article: 392
